20th Nov 2020 07:54
(Alliance News) - AstraZeneca PLC on Friday said Imfinzi has been approved in the US for an additional dosing option, a 1,500 milligram fixed dose every four weeks.
Imfinzi is used in the approved indications of unresectable stage III non-small cell lung cancer after chemoradiation therapy and previously treated advanced bladder cancer.
The Cambridge, England-headquartered pharmaceutical company said this new option is consistent with the approved Imfinzi dosing in extensive-stage small cell lung cancer and will be available to patients weighing more than 30 kilograms.
The approval by the US Food & Drug Administration was based on data from Imfinzi clinical trials, including the Pacific phase III trial which supported the two-week, weight-based dosing in unresectable stage III non-small cell lung cancer, and the Caspian phase III trial which used four-week, fixed-dosing during maintenance treatment in extensive-stage small cell lung cancer.
"This new four-week dosing option gives doctors the choice to cut the number of visits for critical cancer treatment in half and offers a regimen that is more convenient for patients," explained Victoria Villaflor, clinical professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Cancer Center, Los Angeles, California.
"Additionally, it limits potential exposure to infection in the healthcare environment for a population that is especially vulnerable to complications from Covid-19," added Villaflor.
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca